Ben Westphalen, Chair of Translational Research and Precision Medicine Working Group at ESMO, shared some insights from an article by Jonathan D. Schoenfeld et al. on X:

“In Clinical Cancer Research – new data from NCI MATCH:

Arm Z1D highlights new biomarkers in non-colorectal dMMR tumors: NGS-based MSI and immune infiltration predict response to PD-1 blockade with nivolumab.”

Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D

Authors: Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen, Michael J. Overman, Katrina Kao, Latifa F. Jackson, Donna Brunnquell, Xiangning Bu, Christina Coppola, Ping Guan, Jennifer Lee, David Sims, Rebecca Fuchs, Jason L. Weirather, Kathleen L. Pfaff, Lauren Gunasti, Srin Ranasinghe, Stanley R. Hamilton, Victoria Wang, Peter J. O’Dwyer, Catherine J. Wu, Scott J. Rodig, David R. Patton, Lyndsay Harris

Ben Westphalen: New biomarkers in non-colorectal dMMR tumors highlighted in NCI MATCH